Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Treasury Shares (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Treasury Shares for 3 consecutive years, with $8.0 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 100.0% to $8.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.0 million through Dec 2025, up 100.0% year-over-year, with the annual reading at $8.0 million for FY2025, 100.0% up from the prior year.
  • Treasury Shares for Q4 2025 was $200000.0 at Ultragenyx Pharmaceutical, up from $173034.0 in the prior quarter.
  • The five-year high for Treasury Shares was $5.2 million in Q4 2024, with the low at $7812.0 in Q1 2023.
  • Average Treasury Shares over 4 years is $865185.4, with a median of $162344.0 recorded in 2025.
  • The sharpest move saw Treasury Shares skyrocketed 835.96% in 2024, then surged 100.0% in 2025.
  • Over 3 years, Treasury Shares stood at $432000.0 in 2023, then skyrocketed by 825.93% to $4.0 million in 2024, then soared by 100.0% to $8.0 million in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $8.0 million, $8.0 million, and $8.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.